Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TBP.TO
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Tetra Bio Pharma Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 10.58M
- Ent value
- 19.03M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 54.83%
- 1 year return
- -58.33%
- 3 year return
- -50.00%
- 5 year return
- -53.00%
- 10 year return
- -12.50%
Last updated: 2024-12-17
DIVIDENDS
TBP.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 423.36M |
| EPS (TTM) | -0.09 |
| FCF per share (TTM) | -0.02 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -39.80M |
| Net income (TTM) | -39.02M |
| EPS (TTM) | -0.09 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 483.20K |
| Net receivables | 1.58M |
| Total current assets | 2.25M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 3.02M |
| Accounts payable | 7.27M |
| Short/Current long term debt | 1.66M |
| Total current liabilities | 8.93M |
| Total liabilities | 8.93M |
| Shareholder's equity | -5.91M |
| Net tangible assets | -5.91M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.18M |
| Capital expenditures (TTM) | 11.25K |
| Free cash flow (TTM) | -8.20M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -1292.13% |
| Return on Invested Capital | 918.29% |
| Cash Return on Invested Capital | 192.88% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| TBP.TO | S&P500 | |
| Current price drop from All-time high | -98.54% | -6.74% |
| Highest price drop | -99.12% | -56.47% |
| Date of highest drop | 17 Nov 2022 | 9 Mar 2009 |
| Avg drop from high | -76.01% | -11.07% |
| Avg time to new high | 433 days | 12 days |
| Max time to new high | 1413 days | 1805 days |
COMPANY DETAILS
Marketcap
10.58M
Marketcap category
Small-cap
Description
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
Employees
33
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found